In a nutshell This study aimed to investigate the outcomes for patients with chronic lymphocytic leukemia (CLL), with genetic abnormalities (mutated IGHV) and without del(17p)/TP53 mutation, who were treated with the iFCG (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) regimen. This study concluded that this treatment regimen is...
Read MoreIbrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with genetic abnormalities
